{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-073809","form_type":"8-K","ticker":"RYTM","cik":"0001649904","company_name":"RHYTHM PHARMACEUTICALS, INC.","filed_at":"2023-06-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.836422+00:00","generated_at":"2026-06-13T19:05:16.878903+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"confidence":"high","headline":"Rhythm Pharma annual meeting: all proposals approved by stockholders","bullets":["49,290,096 shares (~86.7%) present at June 21, 2023 meeting.","Three Class III directors elected: Bedrosian, McGirr, Meeker with strong majorities.","Ratification of Ernst & Young as auditor passed 49.2M for, 22k against.","Advisory compensation vote approved 38.8M for, 1.9M against, 5.9M abstain."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-073809","json":"https://secwatch.observer/filing/0001104659-23-073809.json","markdown":"https://secwatch.observer/filing/0001104659-23-073809.md","text":"https://secwatch.observer/filing/0001104659-23-073809.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649904/000110465923073809/0001104659-23-073809-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649904/000110465923073809/tm2319441d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T19:05:16.878903+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1e11cb2bddbe3568809cfc107ec9128f3b3a0773","claim":"RHYTHM PHARMACEUTICALS, INC. shareholders approved Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers at the 2023-06-21 meeting.","evidence_excerpt":"Item 3 – Approval, on an advisory (non-binding) basis, of the compensation of the Company's named executive officers.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1649904/000110465923073809/0001104659-23-073809-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-21"}],"fact_type":"shareholder_vote"},{"claim_id":"2477400eb8fd4c6be340ce8567b03e29abb3cba9","claim":"RHYTHM PHARMACEUTICALS, INC. shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm at the 2023-06-21 meeting.","evidence_excerpt":"Item 2 - Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2023.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1649904/000110465923073809/0001104659-23-073809-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-21"}],"fact_type":"shareholder_vote"},{"claim_id":"82eb5904a91edd41a26b64b0edca5b04b50419bf","claim":"RHYTHM PHARMACEUTICALS, INC. shareholders approved Election of three Class III Directors to serve until the 2026 Annual Meeting of Stockholders at the 2023-06-21 meeting.","evidence_excerpt":"Item 1 - Election of three Class III Directors to serve until the 2026 Annual Meeting of Stockholders, and until their respective successors have been duly elected and qualified.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1649904/000110465923073809/0001104659-23-073809-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-21"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}